دورة المؤشرنت للتحليل الفني
50 دينار كويتي
أنت تستخدم أحد المتصفحات القديمة. قد لا يتم عرض هذا الموقع أو المواقع الأخرى بشكل صحيح.
يجب عليك ترقية متصفحك أو استخدام أحد المتصفحات البديلة.
يجب عليك ترقية متصفحك أو استخدام أحد المتصفحات البديلة.
Ulu شباب شنو رايكم في السهم هذا
- بادئ الموضوع siemens
- تاريخ البدء
siemens
عضو نشط
- التسجيل
- 22 سبتمبر 2005
- المشاركات
- 305
نازل خبر
Biotech Stock Alert for La Jolla Pharmaceutical Co. Issued by StockPreacher
Buzz up! 0 Print
Companies:La Jolla Pharmaceutical Co. Related Quotes
Symbol Price Change
LJPC 0.22 0.00
{"s" : "ljpc","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: StockPreacher On Thursday January 14, 2010, 6:50 am EST
DALLAS, Jan. 14, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug company La Jolla Pharmaceutical Co. (Nasdaq:LJPC - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/LJPC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
La Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for Lupus nephritis. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company's wholly owned subsidiary is La Jolla Ltd.
Message Board Search for LJPC: http://www.boardcentral.com/boards/LJPC
In the report, the analyst notes:
"LJPC in mid December announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corp. ("Adamis") (OTCBB:ADMP - News). Upon closing, the combined company will focus on the development and commercialization of therapeutic products for a variety of viral diseases, including hepatitis and influenza. Adamis recently launched a pre-filled Epinephrine syringe and is seeking to generate near-term revenue that can be used to support development efforts for product candidates representing larger market opportunities. It is anticipated that the merged company will be named Adamis Pharmaceuticals Corp. and be headquartered in San Diego, California.
"Research and development expense increased to $51.0 million for the year ended December 31, 2008, from $46.6 million in 2007. The increase in research and development expenses in 2008 from 2007 resulted primarily from an increase in clinical trial expenses of approximately $7.8 million, offset by a decrease in Riquent-related drug production of $4.1 million. Research and development expense of $50.8 million for the year ended December 31, 2008, related to lupus research and development-related expense consisting primarily of Riquent-related clinical trial expenses and clinical drug supply, salaries and other costs related to manufacturing, clinical and research personnel and fees for consulting and professional outside services."
To read the entire report visit: http://www.stockpreacher.com/n/LJPC
See what investors are saying about LJPC at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
Contact:
Biotech Stock Alert for La Jolla Pharmaceutical Co. Issued by StockPreacher
Buzz up! 0 Print
Companies:La Jolla Pharmaceutical Co. Related Quotes
Symbol Price Change
LJPC 0.22 0.00
{"s" : "ljpc","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: StockPreacher On Thursday January 14, 2010, 6:50 am EST
DALLAS, Jan. 14, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug company La Jolla Pharmaceutical Co. (Nasdaq:LJPC - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/LJPC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
La Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for Lupus nephritis. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company's wholly owned subsidiary is La Jolla Ltd.
Message Board Search for LJPC: http://www.boardcentral.com/boards/LJPC
In the report, the analyst notes:
"LJPC in mid December announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corp. ("Adamis") (OTCBB:ADMP - News). Upon closing, the combined company will focus on the development and commercialization of therapeutic products for a variety of viral diseases, including hepatitis and influenza. Adamis recently launched a pre-filled Epinephrine syringe and is seeking to generate near-term revenue that can be used to support development efforts for product candidates representing larger market opportunities. It is anticipated that the merged company will be named Adamis Pharmaceuticals Corp. and be headquartered in San Diego, California.
"Research and development expense increased to $51.0 million for the year ended December 31, 2008, from $46.6 million in 2007. The increase in research and development expenses in 2008 from 2007 resulted primarily from an increase in clinical trial expenses of approximately $7.8 million, offset by a decrease in Riquent-related drug production of $4.1 million. Research and development expense of $50.8 million for the year ended December 31, 2008, related to lupus research and development-related expense consisting primarily of Riquent-related clinical trial expenses and clinical drug supply, salaries and other costs related to manufacturing, clinical and research personnel and fees for consulting and professional outside services."
To read the entire report visit: http://www.stockpreacher.com/n/LJPC
See what investors are saying about LJPC at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
Contact:
siemens
عضو نشط
- التسجيل
- 22 سبتمبر 2005
- المشاركات
- 305
قلطان السهم LJPC Biotech Stock Alert for La Jolla Pharmaceutical Co. Issued by StockPreacher
Buzz up! 0 Print
Companies:La Jolla Pharmaceutical Co. Related Quotes
Symbol Price Change
LJPC 0.22 0.00
{"s" : "ljpc","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: StockPreacher On Thursday January 14, 2010, 6:50 am EST
DALLAS, Jan. 14, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug company La Jolla Pharmaceutical Co. (Nasdaq:LJPC - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/LJPC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
La Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for Lupus nephritis. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company's wholly owned subsidiary is La Jolla Ltd.
Message Board Search for LJPC: http://www.boardcentral.com/boards/LJPC
In the report, the analyst notes:
"LJPC in mid December announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corp. ("Adamis") (OTCBB:ADMP - News). Upon closing, the combined company will focus on the development and commercialization of therapeutic products for a variety of viral diseases, including hepatitis and influenza. Adamis recently launched a pre-filled Epinephrine syringe and is seeking to generate near-term revenue that can be used to support development efforts for product candidates representing larger market opportunities. It is anticipated that the merged company will be named Adamis Pharmaceuticals Corp. and be headquartered in San Diego, California.
"Research and development expense increased to $51.0 million for the year ended December 31, 2008, from $46.6 million in 2007. The increase in research and development expenses in 2008 from 2007 resulted primarily from an increase in clinical trial expenses of approximately $7.8 million, offset by a decrease in Riquent-related drug production of $4.1 million. Research and development expense of $50.8 million for the year ended December 31, 2008, related to lupus research and development-related expense consisting primarily of Riquent-related clinical trial expenses and clinical drug supply, salaries and other costs related to manufacturing, clinical and research personnel and fees for consulting and professional outside services."
To read the entire report visit: http://www.stockpreacher.com/n/LJPC
See what investors are saying about LJPC at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
Contact:
Buzz up! 0 Print
Companies:La Jolla Pharmaceutical Co. Related Quotes
Symbol Price Change
LJPC 0.22 0.00
{"s" : "ljpc","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: StockPreacher On Thursday January 14, 2010, 6:50 am EST
DALLAS, Jan. 14, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug company La Jolla Pharmaceutical Co. (Nasdaq:LJPC - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/LJPC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
La Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for Lupus nephritis. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company's wholly owned subsidiary is La Jolla Ltd.
Message Board Search for LJPC: http://www.boardcentral.com/boards/LJPC
In the report, the analyst notes:
"LJPC in mid December announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corp. ("Adamis") (OTCBB:ADMP - News). Upon closing, the combined company will focus on the development and commercialization of therapeutic products for a variety of viral diseases, including hepatitis and influenza. Adamis recently launched a pre-filled Epinephrine syringe and is seeking to generate near-term revenue that can be used to support development efforts for product candidates representing larger market opportunities. It is anticipated that the merged company will be named Adamis Pharmaceuticals Corp. and be headquartered in San Diego, California.
"Research and development expense increased to $51.0 million for the year ended December 31, 2008, from $46.6 million in 2007. The increase in research and development expenses in 2008 from 2007 resulted primarily from an increase in clinical trial expenses of approximately $7.8 million, offset by a decrease in Riquent-related drug production of $4.1 million. Research and development expense of $50.8 million for the year ended December 31, 2008, related to lupus research and development-related expense consisting primarily of Riquent-related clinical trial expenses and clinical drug supply, salaries and other costs related to manufacturing, clinical and research personnel and fees for consulting and professional outside services."
To read the entire report visit: http://www.stockpreacher.com/n/LJPC
See what investors are saying about LJPC at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
Contact:
دورة المؤشرنت للتحليل الفني
50 دينار كويتي